CRO Quality Benchmarking – Phase IV Service Providers (10th Edition)

Description

Welcome to the 10th edition of ISR’s CRO Quality Benchmarking – Phase IV Service Providers report. As ever, the goal of this report is to provide detailed information to aid in making informed decisions when outsourcing Phase IV work.

230 qualified Phase IV decision-makers participated in our survey to share their insights on topics such as selection drivers, perceptions of providers, and how well provider performance stacked up against their expectations. 30 Phase IV providers received performance evaluations on 6 attributes and 14 study types. In response to customer feedback, ratings on individual study types are new additions to the report this year. Providers are rated on their performance across such study types as Phase IIIb/IV Clinical Studies, Post-marketing Pharmacovigilance, Comparative Effectiveness Research, and Registries, among others. These metrics will be particularly useful to sponsors requiring a provider with stand-out capabilities.

Phase IV CRO Benchmarking

Study sponsors:

  • Make a more informed purchase of Phase IV services by understanding which service providers best fit your company’s needs
  • Broaden your Phase IV CRO evaluation list by accessing peer-based service quality ratings across 6 critical attributes and 14 study types
  • Pinpoint potential delivery concerns early in a sponsor-CRO relationship in order to develop proactive strategies to address potential gaps


Clinical Service Providers:

  • Uncover your own—and competitor—delivery strengths and weaknesses
  • Design messaging to tout your company’s strengths
  • Compete more effectively by understanding buyers’ selection criteria and outsourcing trends
  • Service Provider Selection Process
  • Service Provider Perceptions and Interactions
  • Service Provider Performance and Loyalty
  • Company Service Quality Profiles
  • Study Data

ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive

  • Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
  • Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries.  We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
  • Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.

For additional questions about any of ISR’s reports or custom research services, please contact us at info@ISRreports.com.

CRO Service Provider Attributes Gaining Importance

Service Provider Selection Process

Primary Section Takeaways
Preferred Provider Agreements
Selection Attributes

Service Provider Perceptions and Interactions

Primary Section Takeaways
Phase IV Leadership, Familiarity, and Use
Service Provider Preference
Service Provider Preference among Users
Cost Perceptions
Cost Experience among Users
Summary Table

Service Provider Performance and Loyalty

Primary Section Takeaways
A Note on Performance Calculations
Performance on Delivery Factors
Performance by Study Type

Phase IIIb/IV Clinical Studies
Expanded Access
Post-marketing Safety
Health Economics & Outcomes Research

Customer Loyalty
Customer Loyalty: 3-Year Rolling Average

Company Service Quality Profiles

Chiltern
Covance
ICON
INC Research
inVentiv Health Clinical
IQVIA/QuintilesIMS
Mapi
PAREXEL
PPD
PRA
UBC

Study Data

Phase IV Leaders, Unprompted
Other Responses
Phase IV Leaders, Prompted
Service Provider Familiarity
Service Provider Usage
Service Provider Preference
Service Provider Differentiation
Service Provider Cost Perceptions
Use of Preferred Providers
Number of Preferred Providers
Selection Drivers: Selecting among Preferred Providers
Preferred Provider Attributes Gaining Importance
Selection Drivers: When Not Using Preferred Providers
Selection Drivers: No Preferred Providers
Service Provider Attributes Gaining Importance: No Preferred Providers
Service Provider Drill-downs

Accenture
Chiltern
Clinipace
Cognizant
Covance
DaVita Clinical Research
DCRI-Duke
Eurotrials
ICON
INC Research
inVentiv Health Clinical
IQVIA/QuintilesIMS
Lambda
Mapi
Medpace
NAMSA
Novotech
PAREXEL
PPD
PRA
PRC Clinical
QPS
Radiant
Rho
RTI International
SGS Life Sciences
SynteractHCR
Tata
UBC
Worldwide Clinical Trials

Performance Across Service Providers

Demographics

Company Type
Headquarters Location
Office Location
Job Title
Decision-making Responsibility
Outsourcing Involvement by Phase
Involvement in Clinical Development
Therapeutic Areas of Responsibility
Years of Industry Experience
Age

Additional information

License

, ,